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The American Society for Blood and
Marrow Transplantation (ASBMT) has sub-
mitted comments to the U.S. Food and
Drug Administration, raising concerns
about specific requirements in proposed
new rules for “good tissue practices.”
The draft regulations address methods,
facilities and controls in the manufacture of
human cellular and tissue-based products.
They include labeling requirements, report-
ing of product deviations and adverse reac-
tions, and FDA inspections to enforce com-
pliance. Certain cellular and tissue-based
products that require licensing or pre-mar-
ket approval as biological products or med-
ical devises would be subject to new addi-
tional requirements.
The draft rules are the concluding
phase of a 1997 FDA initiative addressing
safety and product quality in human cellular
and tissue-based products.
Joining ASBMT and other organiza-
tions submitting comments to the agency
was the Foundation for Accreditation of
Hematopoietic Cell Therapy (FAHCT), which
is co-sponsored by ASBMT.
Although most of the elements in the
draft regulations conform to voluntary stan-
dards already adopted by FAHCT, certain
components are discrepancies and differ-
ences that could have a negative impact on
blood and marrow transplantation, accord-
ing to the ASBMT statement.
“Because ASBMT uniquely represents
the physicians who administer transplants
and care for these patients prior to, dur-
ing and after transplantation, we feel it
important to summarize those compo-
nents of the rules proposed by the FDA
that exceed the requirements of FAHCT
Standards that will have an untoward
impact on the practice of transplantation
medicine and potentially inhibit effective
application and continued development of
allogeneic hematopoietic stem cell trans-
plants,” said ASBMT President Richard
O’Reilly, M.D.
Among the ASBMT recommendations to
the FDA were:
• Guarantees that patient-specific infor-
mation remains confidential and does
not become part of a public record
or file.
• Elimination of certain oversight and
audit requirements that would be oner-
ous for smaller transplant centers.
• Elimination of required advance justifi-
cation and authorization for procedure
deviations.
• Elimination of separate reporting of
cleaning and disinfection for each
reagent and with each piece of vali-
dated equipment.
• Simpler labeling requirements for indi-
vidual transplant products.
• Revision of proposed requirements for
expiration dates on cryopreserved
transplants.
• Modification of required reports of
adverse reactions, to make them more
practical and specific to blood and
marrow transplantation.
• Elimination of a requirement that
peripheral and marrow-derived blood
stem cells imported to the United
States must be held for inspection by
an FDA official at the port of entry.
The ASBMT statement also questioned
the accuracy of the FDA’s characterization
of the risks of contamination in hemato-
poietic progenitor cell products and the
agency’s estimates of costs to comply with
the proposed regulations. “The FDA
presents no convincing evidence that
requirements exceeding the FAHCT Stan-
dards will significantly alter the incidence of
contaminated peripheral blood progenitor
cell and marrow cell samples, an incidence
no higher than that recorded for current
transfusion practice,” Dr. O’Reilly said.
Both ASBMT and FAHCT are concerned
that the agency’s estimates for rates of
infection are inflated, and that the projected
costs for compliance are underestimated. A
FAHCT-conducted analysis of compliance
costs indicates about $27,000 in new
expenditures for compliant centers and
nearly $80,000 for non-compliant centers.
The total added costs for the BMT field
would exceed $16 million.
The ASBMT statement concluded that
the proposed new rules offer little benefit
over current FAHCT Standards, but would
substantially add to costs, a burden not likely
to be shouldered by third-party insurers. 
Following are the complete texts of the
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HFA-305
Food and Drug Administration
5630 Fisher’s Lane, Room 1061
Rockville, MD 20852
Re: 21 CFR Part 1271 [Docket No. 97N-484P]: Current Good Tissue Practice for Manufacturers 
of Human Cellular and Tissue-Based Products; Inspection and Enforcement
Dear Sirs/Madams:
I am writing as President of the American Society of Blood and Marrow Transplantation, an organization dedicated to the
continued development of blood and marrow transplantation approaches, their increased safety and efﬁcacy when applied to
lethal disorders of the hematopoietic system, and other sensitive tumors. This organization represents nearly 1,000 members
in the transplant community derived from over 250 transplant centers in the United States and in North and South America.
Our group has extensively reviewed the proposed regulations for 21CFR part 1271 in entitled, “Current Good Tissue
Practice For Manufacturers of Human Cellular and Tissue Based Products; Inspection and Enforcement; Proposed Rule.”
For most of the proposed rules, we congratulate the FDA for its balanced approach and its development of appropriate and
practicable standards for the production of hematopoietic stem cells for transplantation purposes. 
We are also impressed that the vast majority of the rules proposed have already been incorporated in the standards and
guidelines proposed by the American Society for Bone Marrow Transplantation and the International Society of Hemato-
poietic Graft Engineering (ISHAGE) through its accrediting body, the Foundation for the Accreditation of Hematopoietic
Cell Therapy (FAHCT). 
As you know, FAHCT was established in 1994 to speciﬁcally provide standards and guidelines for the transplantation
community. To insure appropriate evaluation and accreditation, FAHCT has established training programs and has also
selected and developed a panel of 300 laboratory and clinical experts in hematopoietic stem cell preparation and transplanta-
tion to conduct the inspections of each center applying for accreditation. The guidelines developed and adopted by FAHCT
form the basis for each center’s accreditation. These guidelines are now widely accepted throughout this country and Europe
and indeed have been approved by most of the major cooperative treatment groups participating in multicenter trials of
transplantation in the treatment of malignancies under the auspices of the NIH and the National Cancer Institute.
In reviewing the proposed rules, we also note, however, several important discrepancies and differences between the
standards and guidelines formulated and adopted by FAHCT and those proposed in the new rules by the FDA. The joint
response of FAHCT, ASBMT and ISHAGE has already detailed the several points in the proposed FDA rules which either
deviate from or are not required by the FAHCT Standards, which raise concerns in the laboratories providing hematopoietic
stem cell grafts. Because ASBMT uniquely represents the physicians who administer transplants and care for these patients
prior to, during, and after transplantation, we feel it important to summarize those components of the rules proposed by the
FDA that exceed the requirements in the FAHCT Standards that will have an untoward impact on the practice of transplan-
tation medicine and potentially inhibit effective application and continued development of allogeneic hematopoietic stem
cell transplants in the treatment of patients.
These points of concern, in the order of their presentation in the proposed rules, are:
1) Sections 1271.160 (b) Functions (7) paragraph 2 and Sections 1271.320 (b) Complaint File. File 
review and copying by the FDA.
The requirement for reports of periodic reviews and analyses of product directions and for maintenance of a complaint
ﬁle for review upon request by the FDA reﬂects the need for quality management tools by facilities producing hematopoietic
stem cells for transplantation. We accept this need. However, it is essential that these functions permit open and frank
reviews. Such reviews within individual centers are privileged, conﬁdential, and not a part of the public record. The FDA
should specify in the ﬁnal rule that the FDA and its employees will guarantee the conﬁdentiality of these reports and that
these reports will not become part of the public ﬁle regarding a center producing or distributing the cell product. 
2) Section 1271.160 (c and d) Authority Over Program and Audits
The requirement for oversight and audits by individuals not engaged in the work of the hematopoietic stem cell process-
ing laboratory will be difﬁcult and may not be practicable for small facilities, where only 1-2 individuals may do this type of
work. If independent oversight and audits are required, individuals at a center not expert in the issues would likely be
recruited. Alternatively, outside experts would need to be recruited at a cost that would likely be prohibitive. These require-
ments are onerous and might well signiﬁcantly reduce the number of donor centers currently participating in the National
Marrow Donor Program, which currently provides up to 30% of the transplants administered worldwide. For these reasons,
we would recommend that this requirement be dropped.
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3) Section 1271.180 Procedures.
“Any deviation from a procedure shall be authorized in advance by a responsible person, recorded and justiﬁed.” Because
of donor to donor variation in yields of hematopoietic stem cells and occasionally, the responses of blood cells to standard-
ized fractionation procedures, it is not possible to predict and authorize deviations in advance. In the context of a hemato-
poietic stem cell transplant, this is particularly the case, since the transplant from a given identiﬁed donor must be adminis-
tered within 1-2 days of completion of myeloablative cytoreduction. Given these circumstances, we would respectfully
recommend that this rule be deleted.
4) 1271.195 Environmental Control and Monitoring (a) General and (e) Records.
The intent of these rules is appropriate, and most of the speciﬁc requirements are already part of the FAHCT guidelines.
However, certain features of the rules need to be revised to make them practicable and not inappropriately burdensome.
Given the fact that the papers cited by the FDA regarding the incidences of contamination of both manipulated and
unmanipulated hematopoietic stem cell preparations derived from marrow and blood quote rates which are not different
from those published for conventional blood products such as platelets and red cells, vide infra it is unduly onerous to
require the cleaning and disinfection of rooms and equipment that is required for drug manufacture for facilities processing
multiple individual hematopoietic stem cell products when other control systems such as HEPA ﬁltered laboratory hood, are
in place to prevent contamination. Procedures and systems such as are called for by FAHCT and AABB for blood cell pro-
cessing facilities are and should be sufﬁcient.
Similarly, the demand for record keeping which may be useful in the manufacture of large lots of drugs is unduly burden-
some and non-practicable for a facility producing small or large numbers of individual hematopoietic stem cell components.
The processing records for each stem cell preparation should, as requested by FDA and FAHCT Standards, identify supplies
and reagents used for processing. The converse, that is, to have separate records of each transplant prepared with each
reagent and with each piece of validated equipment, is prohibitively time-consuming. Again, we believe this requirement
should be dropped and that the guidelines recommended by FAHCT would be sufﬁcient.
5) 1271.220 Process Controls (b) Processing Material and (c) Pooling.
(b) The section on Processing Material should be amended to state that validated procedures shall be established to insure the
appropriate use and removal of processing material and that the use of these procedures in the preparation of the stem cells be
documented. It is not possible for a center to test, on a case by case basis, that processing materials have actually been eliminated.
(c) The section on pooling is appropriate for hematopoietic stem cell fractionation as it is currently practiced. However,
with the current development of several strategies for inducing transplant anergy and, conversely, for generating donor type
alloreactive T-cells and T-cells speciﬁc for a patient’s cancer for adoptive cell therapy, this rule will soon be outdated and
restrictive. Rewording of the rule to include the phrase “Unless required by a specialized approved protocol….” Would avoid
these future restrictions and facilitate rather than inhibit progress.
6) 1271.250 Labeling Controls
These rules need to be streamlined along lines required by FAHCT and AABB which provides for coded identiﬁcation of
donor, identiﬁcation of intended recipient and critical information regarding donor suitability and the type of processing
used. The information called for in the rule is exorbitant for identiﬁcation of individual transplant products.
7) 1271.260 Storage
Expiration dates are appropriate for conventional blood products, or drugs with deﬁned shelf-lives. At present, the shelf-
life of appropriately cryopreserved hematopoietic stem cells from peripheral blood, marrow or umbilical cord blood is not
established. The rule needs to be revised to reﬂect this. Arbitrary assignment of expiration dates for such cryopreserved
transplants is, at this stage, unjustiﬁed.
8) 1271.350 (a) Adverse Reaction Reports
The requirement for reporting any adverse reaction that necessitates medical or surgical intervention goes well beyond
current FDA guidelines for reporting adverse drug reactions. Furthermore, since transplants of marrow, peripheral blood
stem cells and umbilical cord cells can be rejected and conversely, often cause reactions such as graft vs. host disease, which
can be fatal, this rule needs to be revised and better targeted.
9) 1271.420 Human cellular and tissue-based products offered for import (b)
This rule speciﬁes that imported hematopoietic stem cell transplants would each have to be held until released by the FDA.
The rule is not acceptable to the hematopoietic stem cells transplant community. Unless there is an FDA ofﬁcer available
every minute of every day and night to immediately approve the 2000-3000 unrelated marrow and PBSC transplants that
enter or leave this country each year, it cannot and must not be enacted. Marrow and peripheral blood stem cells are highly
perishable. More importantly, the potential recipient of such a transplant will have completed supralethal myeloablative con-
ditioning by the time the transplant arrives. To have such a transplant on hold, while an ofﬁcial at an airport tries to contact
an FDA ofﬁcial to approve its import is, at this stage in the history of unrelated hematopoietic stem cell transplants, unethi-
cal and serves no useful purpose.
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In addition to the enclosed speciﬁc comments, requests and suggestions regarding the proposed rules, we also wish to
express, for the record, the serious concerns and reservations of the transplant community regarding the accuracy of the
FDA’s estimates of the risks associated with hematopoietic stem cell transplants in the absence of the proposed rules and the
costs and beneﬁts of implementing these rules as proposed.
While we completely concur with the FDA’s objective of providing safe transplants with the lowest possible risk of
microbial contamination, a perusal of available literature and a critical review of the papers cited on page 1547 of the pro-
posed rules indicates that the risks to transplant recipients are greatly overestimated.
First, it should be noted that the peripheral blood progenitor cells and marrow cell samples described in the papers by
Webb et al and by Espinosa et al were largely derived from autologous donors who had received multiple prior therapies,
and, indeed, often required multiple harvests to obtain targeted doses of stem cells (82% in the series quoted by Webb et al.,
97% in that of Espinosa et al). This is an important aspect of these studies, since many of these patients likely had low counts
at time of harvest, would be likely to have had an indwelling catheter for extended periods prior to harvest, and would be at
high risk for catheter infection at time of harvest. Thus, the risks of contamination quoted for PBMC (2.4% for Webb et al.;
0.2% for Espinosa et al.) would be expected to be at the highest end of frequencies. In fact, the incidences quoted are, in one
case, no higher than, and in the other, lower than the incidences of contaminated blood products reported in several series
for platelet or red blood cell transfusions. Strikingly also, the rate of contamination for monoclonal antibody treated and
CD34 selected cells reported by Webb et al did not differ signiﬁcantly from that of unmanipulated peripheral blood stem
cells collected like a normal leukapheresis in a totally closed system.
Based on the data presented, there is no convincing evidence to suggest that the added rules called for will signiﬁcantly
alter the incidence of contaminated peripheral blood progenitor cell and marrow cell samples, since it is no higher than that
recorded for current transfusion practice.
As an aside, it should also be noted that the autologous stem cell factions described by Webb et al and Espinosa et al
would not be subject to the proposed FDA rules.
Secondly, the rates of infection quoted in the FDA document are inﬂated. While 13.7% of patients developed fever in
the early post transplant period, only 2.73% were actually culture positive. In the two cases reported, the organism in the
stem cell graft was subsequently cultured from the patient. As in all other reported series, the infection was effectively treated
by antibiotics. In no other case was a positive culture documented. Given the high rate of fever in patients treated with
chemotherapy without a stem cell graft at this stage post treatment, the 2.73% incidence is the more accurate ﬁgure.
Thus, if the true rate of infection is applied, even using the high rate of 2.4% for contaminated samples reported by
Webb et al, the actual number of potential lethal infections is: 
8000 × 0.024 × 0.0273 × 0.58 PBSC = 3 patients.
If the rate of 0.2% reported by Espinosa is applied, the number is:
8000 × 0.002 × 0.0273 × 0.58 PBSC = 0.25 patients.
These numbers are strikingly lower than the 15 patients quoted by the FDA.
Thirdly, it must be noted that the added inpatient costs for treatment of these infections are grossly inaccurate, since
each of these patients would be expected to be in the hospital as an inpatient during the same time to receive support follow-
ing myeloablative therapy.
I will not reiterate the cost accounting provided by FAHCT in its assessment of the added costs of the FDA rules beyond
those incurred by practices already required by FAHCT for accreditation. Sufﬁce it to say they are signiﬁcantly higher than
the FDA estimates and likely not sustainable by smaller centers.
In summary, while we applaud the efforts of the FDA, and appreciate their responsiveness to FAHCT as reﬂected by the
similarities between the proposed FDA rules and the existing FAHCT standards and guidelines, we cite several new rules that
will have a negative and potentially severe impact on the clinical practice of transplantation. By placing unduly burdensome
requirements on transplant collection centers, certain of these rules may also force the closing of many small collection centers
in the United States and likely limit access to hematopoietic stem cell transplants for patients in our own and other countries
participating with the National Marrow Donor Program. The latter problem is particularly worrisome since it would reduce
the potential pool of unrelated donors for its current level of 7 million to 4 million, and deny hundreds of patients a potentially
curative graft. Lastly, we question the risk/beneﬁt ratio proposed since, 1) the actual rates of contamination of stem cell trans-
plants cited do not exceed those reported for unmanipulated platelet and red cell transfusion, 2) the number of severe infec-
tions to be presented is strikingly smaller than estimated and, more importantly, not likely to be affected by the rules proposed
and, 3) the additional costs, which are not likely to be deferred by third party insurers, are exorbitant.
We respectfully suggest that the rules cited in this letter be deleted or modiﬁed. We also suggest that the existing guide-
lines required by FAHCT are sufﬁcient to insure the safety of hematopoietic stem cell transplants we all wish to provide.
Thank you for your consideration.
Sincerely yours,
Richard J. O’Reilly, M.D.
President, American Society for Bone Marrow Transplantation
FAHCT Letter to the Food and Drug Administration
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May 7, 2001
Food and Drug Administration Docket
Dockets Management Branch
HFA-305
Food and Drug Administration 
5630 Fisher’s Lane, Room 1061
Rockville, MD 20852
Re: 21 CFR Part 1271 [Docket No. 97N-484P]: Current Good Tissue Practice for Manufacturers of Human
Cellular and Tissue-Based Products; Inspection and Enforcement 
The following is the response of the Foundation for the Accreditation of Hematopoietic Cell Therapy (FAHCT) to the
Food and Drug Administration’s proposed regulations for Current Good Tissue Practice for Manufacturers of Human Cel-
lular and Tissue-Based Products; Inspection and Enforcement published in the Federal Register on January 8, 2001.
In addition to the speciﬁc proposed regulations discussed in this letter, FAHCT and it’s parent organizations, the Inter-
national Society of Hematotherapy and Graft Engineering (ISHAGE) and the American Society of Blood and Marrow
Transplantation (ASBMT), feel strongly that the risks from the contaminated hematopoietic progenitor cell (HPC) products
and the costs of implementing the proposed regulations included in the 21 CFR Part 1271 document are highly ﬂawed and
misleading. As we discuss below, the risks to the patient are overstated and the estimates of the costs of complying with the
proposed FDA regulations under-estimated. 
Risks of Contaminated HPC Products and Cost Estimates of Compliance
The statements made regarding the morbidity and costs incurred because of contaminated hematopoietic transplant
products are greatly exaggerated, misleading and fundamentally incorrect. Infections frequently occur following hemato-
poietic transplantation related to pancytopenia and are not due to contaminated PBSC. The costs involved with hemato-
poietic transplantation are directly related to supportive care required during the period of chemotherapy induced myelosup-
pression post transplant. Although contamination of the hematopoietic transplant may rarely occur in hematopoietic
transplant collections, it generally involves relatively nonpathogenic skin ﬂora. Since it is often not feasible to collect addi-
tional transplant products, and the transplant can be life saving, a number of cases have been reported using cells contami-
nated by S. epidermidis without major complication or prolongation of hospitalization; patients are generally treated with
appropriate antibiotics during the cell infusion. The toxicity of DMSO is readily managed by limiting the amount of DMSO
infused. ICU admissions in transplant recipients are generally the result of high dose chemotherapy and infections unrelated
to contaminated cell infusions; it is well documented that these infections are acquired from ﬂora colonizing the gastroin-
testinal and respiratory tracts, not contaminated transplant products. Thus the calculations regarding lives saved and costs
reduced by the proposed measures are fundamentally ﬂawed. We are unaware of evidence that methods currently in use by
the medical community have resulted in avoidable morbidity or mortality. 
Specifically relating the FDA risk and cost estimates:
1) FDA estimates that the average stay for a bone marrow transplant patient in 1994 was 35 days at a cost of $168,573.
Costs and average length of stay in 2001 are much different than in 1994; again, this ﬁgure is related to generally sup-
portive care needed for a transplant recipient and is not due to contamination of the graft.
2) The FDA attempts to estimate the impact of a contaminated HPC product for immunosuppressed recipients. The marginal
risk of a contaminated product over that of infection from other causes in immunocompromised hosts is extremely small in
aggregate. As indicated there are many reports of successful transplantation despite low level contamination of the graft.
3) The dimethylsulfoxide (DMSO) toxicity attributed to large volume peripheral blood progenitor cell infusions is overesti-
mated. The use of DMSO has no impact on cost or toxicity in the vast majority of HPC recipients.
4) FDA estimates that 2.4% of peripheral blood progenitor cell products are contaminated and suggest there is a 13.7%
incidence of infection in patients receiving contaminated HPC products (net infectious risk: 0.33%). The incidence of
infection cited greatly overestimates the risk of infection caused by the HPC product. Further, the vast majority of conta-
minated HPC products contain skin ﬂora (gram-positive cocci) that are not life-threatening, are easily treated in the out-
patient setting, and do not contribute at all to inpatient hospital costs as suggested by the analysis. These infections
almost never cause hospital admission or prolongation of hospital stay. In the same reference cited by the FDA,1 there
were no irreversible sequelae noted following infusion of contaminated product.
5) Intensive Care Unit (ICU) admission. The FDA cited data of a 57% death rate in transplant patients admitted to ICU
with infections versus a 13% death rate in patients with no infections is not relevant to the cost of infusing contaminated
HPC products, but rather the cost and risk of endogenously acquired infection in transplant patients. There are no data
to suggest that patients who receive contaminated HPC products require ICU care or have a higher death rate than simi-
lar transplant patients who receive uncontaminated products. The FDA estimates that 15 patients a year could get infec-
tion from contaminated HPC products and that 7 of these patients would die. As noted above, death from contaminated
product infusions is extremely rare. Of the estimated 15 patients, it is highly likely that the mortality will be zero and that
no additional hospital days would be required for treatment. The anticipated additional cost per patient is less than $500
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for the requisite two-week course of vancomycin or similar antibiotic. Transplant recipients generally receive antibiotic
prophylaxis as a standard of care and thus, would not receive additional days of antibiotic treatment, even if a contami-
nated graft was administered. Thus, for an estimated cost of no more than $7500/yr, and no excess mortality risk, the
agency proposes regulation costing millions of dollars per year (see below). 
6) The FDA document states that the aggregate annual costs for a facility to come in to compliance with their proposed
regulations would be $9,256.81. That calculation was derived from one-time costs of $3,571,049; annual costs of
$3,194,292 and then total annualized costs of $3,702,027 calculated for 400 facilities. However, on page 1526, table 2,
column 5, the costs of complying with the proposed regulations were broken down by speciﬁc regulation, for both com-
pliant (i.e. FAHCT accredited) and noncompliant facilities. We took the FDA’s estimated costs from table 2 and deter-
mined that for a compliant (FAHCT accredited) facility, the cost per facility per year would be $27,291 and for noncom-
pliant facilities $79,437. The annual costs for 300 centers that were determined to be compliant would therefore be
$8,187,300. For the 100 facilities estimated to be noncompliant, the cost would be $7,943,000. Thus the total annual
costs of compliance would actually be $16,131,000. If this additional cost were associated with additional safety for the
patients there would be less concern. However, as discussed below, there are no data to suggest that any of the proposed
regulations, particularly for compliant facilities, would end up improving the safety and thus clinical care of our HPC
transplant patients. 
The following proposed regulations are of concern to FAHCT:
1271.150 (b) paragraph 2: Facility responsible for release criteria
Further clariﬁcation of who is responsible is required. It is not clear whether this responsibility pertains to the manufac-
turing facility or just the distributor. If the distributor is an institutional laboratory that receives a product that was processed
at a commercial laboratory, this requirement would be unduly burdensome. 
1271.160 (b) Functions (7) paragraph 2: Confidentiality
FDA is requiring in section Sec. 1271.160 (b)(7) that the periodic review and analysis of all product deviations be made
available for review upon inspection and for submission to FDA upon request. Furthermore, FDA is requiring in section
1271.320(b) that a complaint ﬁle to be maintained shall also be made available for review and copying upon request from an
authorized employee of the FDA. 
Both the periodic audit of product deviations and the collation of a complaint file are tools of quality management.
The proper conduct of quality management activities requires open and truthful review of adverse outcomes within the
facility conducting the audit. FDA should state in the final rule that FDA and its employees shall guarantee that the con-
fidentiality of these quality management activities will be strictly maintained by FDA and that records or copies of such
records shall not become part of the public record regarding a manufacturer or distributor of cellular or tissue-based
products.
1271.160 (c) Authority over program
This is a departure from the requirements that the agency has imposed on other areas such as blood and blood compo-
nents, where the more general wording of the regulation [21CFR 606.100 (b) (19) (c)] may on occasion lead to a single per-
son doing actual work and ﬁnal review, separated in time and function. In small laboratories with only a single technician it
may not be possible for an independent person to have oversight. This requirement will limit access to care by limiting the
number of programs available who could provide additional stafﬁng. The proposed tissue regulation is at least as stringent as
cGMP requirements in 21CFR 211.
1271.160 (d) Audits (2) Acceptable personnel
As above, in small laboratories with only a single technician, there may not be an alternative knowledgeable person able
to perform the audits. We think it would be inappropriate to limit access to care by limiting programs that had a knowledge-
able staff person but not another knowledgeable person to perform the audit. 
1271.170 Organization and personnel (b) Competent performance of functions
We recommend that “training and documentation of competency” be used rather than “education and experience.” The
latter are more vague and do not ensure competent performance of the procedure. 
1271.180 Procedures (6) Deviations
Some deviations, such as those occurring in process, cannot be authorized in advance. 
1271.180 (last sentence) Archiving records for at least 10 years
This requirement to maintain obsolete procedures for ten years is inconsistent with record retention requirements where
documents pertaining to manufacture of a product should be kept for at least 10 years after implantation, transplantation,
infusion, or transfer of the product. [Section 1271.270 (e)]. We believe the longer retention of obsolete procedures (i.e., for
ten years after transplantation) to be more appropriate and request clariﬁcation of FDA intent.
1271.190 (c) Facilities (4) Cleaning and sanitation activities
Clariﬁcation of “signiﬁcant” cleaning and sanitation activities is necessary. Such activities could include mopping the
ﬂoor or washing the cabinets. We believe it would be unduly burdensome to keep records of mopping the ﬂoor for 10 years.
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Alternatively, changing the air handling ﬁlters is a signiﬁcant cleaning activity that would have more relevance to the quality
of the processing procedures and records of such an activity warrant retention. 
1271.195 Environmental control and monitoring (3) Cleaning/disinfecting rooms
We interpret this to mean that this type of cleaning and disinfection would not apply to most stem cell laboratories per-
forming routine (minimally manipulated) processing procedures. If that is not the case, it is burdensome to require disinfec-
tion of all rooms when other control systems to prevent contamination are in place. 
1271.195 (5) Environmental monitoring for “organisms”
There is no consensus from current expert opinion on what “organisms” to monitor. This regulation would have to be
more speciﬁc to be meaningful. 
1271.200 Equipment (c) Calibration of equipment
We object to the requirement for calibration of computers since they do not measure anything. Validation should
be sufficient. 
1271.200 (e) Records (2nd sentence) Records of recent maintenance, cleaning, etc.
Such records cannot physically be kept on small instruments such as pipettes. A central repository of such records should
be sufﬁcient. 
1271.200 (e) Records (3rd sentence) Records of the use of each piece of equipment 
The instrument used to process a product is already documented on the processing record. To require listing each
product process for each piece of equipment does not add to the safety or quality of the product and is unnecessarily
burdensome. 
1271.210 Supplies (c) Records (3) Records of each supply or reagent
The supplies and reagents used to process an HPC product are already on the processing record. As above, to require
listing each product process for each pipette or bottle of medium does not add to the safety or quality of the product and is
unnecessarily burdensome. 
1271.220 Process controls (b) Processing material
It is not always physically possible to document that the processing material has been removed from the product. For
example it is not possible to determine exactly how much ﬁcoll is left in the HPC product to be issued. It should be sufﬁcient
to document that validated procedures were used in processing. 
1271.210 (c) Pooling of human cells from two or more donors
This requirement conﬂicts with the philosophy of the regulatory model which holds that, as technology becomes more
standard, the requirements become less burdensome, not more.2 Although currently generation of cellular products such as
cytoxic T lymphocytes or dendritic cells are typically performed under IND, this may not be the case as these procedures
become more standard. Such a requirement will stiﬂe technology transfer and ultimately impact adversely on patient care. 
1271.250 Labeling controls (3) Documentation required for distributed HPC products
“Distribution” needs to be deﬁned. If the product is going from the HPC laboratory to the clinical unit of the same pro-
gram, detailed documentation of the donor testing does not need to accompany that product as it can be found in the labora-
tory. It is burdensome to include all the speciﬁc results of the testing and doesn’t improve the quality of the product. It is suf-
ﬁcient to provide the statement of suitability including the speciﬁcs only when there is a product deviation. If distribution
means distribution outside of the institution then such documentation makes more sense. 
1271.260 Storage (b) Temperature (2) Temperature limits
All three parameters (ensuring function and integrity, preventing deterioration, and inhibiting infectious agent growth)
may not be optimal at the same temperature, and in fact are likely to be optimal at different temperatures. Some HPC prod-
ucts are held at room temperature in the absence of preservatives or antibiotics. That temperature might be optimal for pre-
serving integrity and function, but allow growth of some infectious agents. Each facility will have to prioritize those three
parameters and develop standard operating procedures that describe the acceptable temperature limits for the products in
their own institution, based on their own validation to ensure integrity, etc.
1271.260 Storage (c) Expiration date
The safe duration of cryopreservation for an HPC product is unknown at this time and will take years to validate.
1271.270 Records (c) Other record keeping requirements (5th sentence) Donor suitability records in English
Clariﬁcation is required here, as clearly English translations would not be required for foreign facilities that are pro-
cessing products to be distributed outside the United States. This should be stipulated for products distributed within the
United States.
1271.290 Tracking (d) Product information
The manufacturer has no authority over the content of the medical record. It should be sufﬁcient to provide paper docu-
mentation appropriate for the medical record and notice of the Federal Regulations requiring that the information be placed
in the medical record. 
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1271.290 (f) Consignees
The manufacturer has no authority over the content of the medical record and may not have permission to review the
content of the record at a later time. It should be sufﬁcient to provide the paper documentation appropriate for medical
record in notice of the Federal Regulations requiring that the information be placed in the medical record. 
1271.320 (b) Complaint file (3rd sentence) File review and copying by the FDA 
Copying ﬁles is a breach of conﬁdentiality that is not acceptable. If this is required, the FDA must ensure that patient-
speciﬁc information does not become part of the public record. 
FDA is requiring in section Sec. 1271.160 (b)(7) that the periodic review and analysis of all product deviations be made
available for review upon inspection and for submission to FDA upon request. Furthermore, FDA is requiring in section
1271.320(b) that a complaint ﬁle to be maintained shall also be made available for review and copying upon request from an
authorized employee of the FDA. 
Both the periodic audit of product deviations and the collation of a complaint ﬁle are tools of quality management. The
proper conduct of quality management activities requires open and truthful review of adverse outcomes within the facility
conducting the audit. FDA should state in the ﬁnal rule that FDA and its employees will guarantee that the conﬁdentiality of
these quality management activities will be strictly maintained by FDA and that records or copies of such records shall not
become part of the public ﬁle regarding a manufacturer or distributor of cellular or tissue-based products.
1271.350 Reporting (a) Adverse reaction reports (1) Adverse reaction information (iv) Medical or surgical
intervention
This requirement is too vague and nonspeciﬁc. Medical intervention could be giving Benadryl and Tylenol. Requiring this type
of intervention to be reported is overly burdensome and will not improve the quality of the HPC product or patient care in general. 
1271.350 (b) Reports of product deviations (1)
Reporting minor and unimportant deviations should not be required. More speciﬁcs on how serious a deviation needs to
be to require reporting should be provided. 
1271.420 Human cellular and tissue based products offered for import (b) Holding products until release
It is medically unsafe to hold fresh HPC products that would need to be processed and infused without cryopreserva-
tion, for FDA review. This requirement is not logistically feasible, and has a high chance of jeopardizing the quality of the
products and thus seriously compromising transplant patient care. This would require that the FDA be available 24 hours a
day 7 days a week to deal with HPC products coming from overseas. Even those products that are cryopreserved will have
limited duration before thawing occurs; the FDA could ultimately be responsible for adversely affecting the integrity and
function of the products. 
In summary, it appears that the proposed FDA regulations offer little additional beneﬁt over the FAHCT Standards that
are currently in place. Given that FAHCT is already inspecting to standards which are very close to the proposed regulations
we once again offer our services to improve the quality of care and HPC products provided to our patients. We look forward
to continued dialog on this and other issues. 
Sincerely,
Elizabeth J. Shpall, MD, President, FAHCT
Phyllis Warkentin, MD, Chairman, FAHCT Inspection and Accreditation Committee
Adrian Gee, PhD, Secretary, FAHCT
Richard Champlin, MD, Vice-President, FAHCT
Allen Eaves, MD, Treasurer, FAHCT
C. Fred LeMaistre, MD, Board Member, FAHCT
Scott Rowley, MD, Board Member, FAHCT
William Vaughan, MD, Board Member, FAHCT
Patrick Beatty, MD, Board Member, FAHCT
Helen Heslop, MD, Board Member, FAHCT
Linda Kelley, PhD, Board Member, FAHCT
Frank Smith, MD, Board Member, FAHCT
Richard O’Reilly, MD, President, American Society for Blood and Marrow Transplantation
Robert Negrin, MD, President, International Society for Hematotherapy & Graft Engineering
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